Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) SVP Lauren Riker sold 6,000 shares of Pacira BioSciences stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $36.32, for a total value of $217,920.00. Following the transaction, the senior vice president owned 62,284 shares of the company’s stock, valued at $2,262,154.88. The trade was a 8.79% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pacira BioSciences Stock Performance

NASDAQ:PCRX traded down $0.08 on Friday, hitting $36.31. The company’s stock had a trading volume of 4,689,955 shares, compared to its average volume of 1,974,222. The company has a current ratio of 5.04, a quick ratio of 3.94 and a debt-to-equity ratio of 0.54. The stock has a fifty day moving average of $25.56 and a two-hundred day moving average of $24.59. The firm has a market capitalization of $1.45 billion, a P/E ratio of 103.75 and a beta of 0.25. Pacira BioSciences, Inc. has a one year low of $18.80 and a one year high of $36.46.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%. The company had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. During the same period last year, the firm posted $0.74 earnings per share. The business’s revenue was up 6.2% on a year-over-year basis. Research analysts predict that Pacira BioSciences, Inc. will post 1.86 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on PCRX shares. Oppenheimer assumed coverage on shares of Pacira BioSciences in a report on Wednesday, September 23rd. They issued an “outperform” rating and a $32.00 price objective on the stock. JPMorgan Chase & Co. raised shares of Pacira BioSciences from an “underweight” rating to a “neutral” rating and set a $36.50 target price for the company in a report on Thursday. Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 26th. Weiss Ratings raised shares of Pacira BioSciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Finally, HC Wainwright restated a “neutral” rating and set a $36.50 price objective (down from $38.00) on shares of Pacira BioSciences in a research report on Friday. One analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $33.33.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new position in shares of Pacira BioSciences during the 2nd quarter worth approximately $7,532,000. Bank of America Corp DE acquired a new stake in shares of Pacira BioSciences in the second quarter valued at approximately $6,089,000. Empowered Funds LLC bought a new stake in shares of Pacira BioSciences in the second quarter valued at approximately $5,076,000. PDT Partners LLC bought a new stake in shares of Pacira BioSciences in the second quarter valued at approximately $3,358,000. Finally, Man Group plc acquired a new stake in Pacira BioSciences during the second quarter worth approximately $3,181,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Key Stories Impacting Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Viatris agreed to buy Pacira for $36.50 per share in cash, valuing the equity at approximately $1.65 billion. The transaction gives shareholders a defined exit price and is expected to close by the end of 2026, subject to customary conditions. Viatris acquisition announcement
• Positive Sentiment: Viatris will add Pacira’s marketed non-opioid pain therapies, EXPAREL and ZILRETTA, along with a clinical-stage gene therapy candidate. Viatris expects the deal to expand its pain portfolio and be immediately accretive to its financial guidance metrics.
• Neutral Sentiment: RBC said a superior competing bid is unlikely, reducing the prospect of a higher offer but also lowering takeover uncertainty. The stock’s upside is therefore largely capped near the $36.50 consideration unless another bidder emerges. RBC superior bid analysis
• Neutral Sentiment: Analyst actions largely reflect the announced deal: JPMorgan upgraded PCRX to neutral, while RBC and Truist raised targets to $36.50 and maintained sector perform or hold ratings. HC Wainwright maintained neutral with a $36.50 target, and Jefferies kept hold with a $36.00 target.
• Negative Sentiment: Several shareholder-rights law firms are investigating whether Pacira’s board obtained fair value and conducted an adequate sale process. These investigations could create legal or procedural distractions, although no wrongdoing has been established. Shareholder investigation

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.